

**ROSWELL PARK CANCER INSTITUTE CORPORATION  
SPECIAL MEETING  
OF THE  
BOARD OF DIRECTORS**

A Special Meeting of the Board of Directors of Roswell Park Cancer Institute Corporation was held on Wednesday, March 1, 2023 at 8:30 a.m. in the Scott Bieler Clinical Science Center, 9<sup>th</sup> Floor, Patrick P. Lee Board Room.

**Present:** Gregory Daniel, MD (*Virtual*)  
Linda A. Dobmeier (*Virtual*)  
Leecia Eve, Esq. (*Virtual*)  
Donna Gioia  
Anne D. Gioia (*Virtual*)  
Candace S. Johnson, PhD, President & CEO  
Kenneth A. Manning, Esq.  
Gail Mitchell, Esq. (*Virtual*)  
Elyse NeMoyer (*Virtual*)  
R. Buford Sears (*Virtual*)  
Patrick Toye, Representative for New York State Commissioner of  
Department of Health (*Virtual*)

**Excused:** Michael L. Joseph, Chairman  
Dennis Szeffel

**Staff Present**

**by Invitation:** Renier Brentjens, MD, PhD, Deputy Director & Chair, DOM  
Marco Davila, SVP & Associate Director of Translational Research  
Betsy Doty-Lampson, Board Administrator  
Patrick Emmerling,  
Ryan Grady, Chief Financial Officer  
Dale Henry, Chief Scientific Operations Officer  
James C. Kennedy, Vice President, Government & Community  
Relations  
Anthony Putrelo, Vice President of Facilities  
Thomas Schwaab, MD, PhD, Chief of Strategy, Bus Dev & Outreach  
Michael B. Sexton, Esq., Sr. Vice President & Chief Legal Officer,  
Corporate Secretary  
Jeff Walker, EVP - Operations & Transformation

**Guest:** Pamela Jacobs

## Opening Remarks

Mr. Sears opened the meeting welcoming all and thanking everyone for their attendance. He indicated that the purpose of the meeting was to review for approval the cGMP expansion project, which he believes will be a transformational project for Roswell Park, and also to approve a separate capital project.

## cGMP Facility

Dr. Brentjens started the presentation indicating the intent is that Roswell Park is to be a global destination for cell therapy and a leader in novel therapies. He noted that enhancing the infrastructure for cell manufacture with new vector and cell therapy production capacity, will make Roswell Park a leader in the area of Chimeric Antigen Receptor (CAR) T-Cell technology. This project involves expansion of Roswell Park's existing six (6) room facility. In three to five years, the project will involve construction of fourteen (14) more rooms. The leadership team for the cGMP project is comprised of Dr. Renier Brentjens (Director), Dr. Marco Davila (Medical Director), Dr. Pawel Kalinski (Scientific Director) and Chris Choi, Ph.D., M.B.A. (Technical Director). An oversight committee is being developed, to include outside parties to ensure the facility is operated to benefit Roswell Park. Dr. Brentjens noted that the facility will be a source of vectors and cell lines for outside industry and will also provide product for clinical trials at Roswell Park. It is expected that 40-60% usage will be in this manner making vectors and cell lines for the industry to do clinical trials here at Roswell Park.

---

Mr. Grady noted that funding in the amount of \$30M in grant support has been proposed by Empire State Development Corporation to fund capital and operations with the potential of 60-65 new jobs being created. Mr. Grady went over the business plan and key assumptions. He reviewed client mix projections, utilization and projected revenue method indicating 70% usage of the facility to supply clinical trials work at Roswell Park and 30% of business being to supply commercial entities for their own projects having no connection to Roswell Park. Mr. Grady then went through the five (5) year financial projections for the facility. There was a question about the business plan and discussion about establishing a training program for technician to provide a pipeline of staff.

*After full discussion, there was a motion by Mr. Manning to approve the cGMP expansion project as proposed by management including the projected five (5) year expenditures of \$98,826,000 composed of capital cost of \$32,600,000 and capital related operating expenditures of \$66,226,000. The motion was seconded by Donna Gioia, and unanimously approved.*

## Gratwick, BSB and the C&V Annex Roofs


Mr. Sexton gave a presentation on proposed roof replacements required for the Basic Science Building and the C&V Annex. He indicated that the project will cost ~\$1.7M and is in the Facilities FY'24 capital budget. He noted that the campus roofs are inspected annually and these two (2) were identified in the last report as the top priorities. The Basic Science was replaced in 1995 (28 years ago), 13,100 sq. ft. and the C&V Annex was replaced in 1992 (31 years ago), 2,200 sq. ft. both having

1-2 years of life left. This project was submitted through an RFP process. There were two (2) bids and Elmer Davis was low bid by \$340K.

*A motion to approve the roof replacement project was made by Mr. Manning, seconded by Donna Gioia and unanimously approved.*

*There being no further business, a motion for adjournment was made, duly seconded, and unanimously carried.*

Respectfully submitted,

  
\_\_\_\_\_  
Michael B. Sexton, Esq., Secretary